Stay updated with breaking news from Humacyte board. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) saw a significant growth in short interest in September. As of September 30th, there was short interest totalling 15,800 shares, a growth of 192.6% from the September 15th total of 5,400 shares. Based on an average daily volume of 4,200 shares, the short-interest ratio is presently 3.8 days. […] ....
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 5,250,000 shares, a growth of 38.2% from the August 31st total of 3,800,000 shares. Based on an average trading volume of 670,100 shares, the short-interest ratio is […] ....
By Ben Glickman Oracle reported fiscal first-quarter growth in its cloud business slowed sequentially and compared to the year-ago quarter. Oracle's total. ....
Humacyte, Inc. (HUMA), a clinical-stage biotechnology company focused on universally implantable, bioengineered human tissue at commercial scale, announced Tuesday positive top line results from its V005 Phase 2/3 trial of the Human Acellular Vessel or HAV in vascular trauma repair. ....
Cantor Fitzgerald reaffirmed their overweight rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $6.00 price objective on the stock. Several other brokerages have also recently weighed in on HUMA. Benchmark reiterated a buy rating and issued a […] ....